You are here

Article Text

Article menu
Download PDFPDF
Therapeutics
Randomised clinical trial
Novel anticoagulants in patients with mechanical heart valves
  1. Ralph A H Stewart
  1. Department of Cardiology, University of Auckland, Auckland City Hospital, Auckland, New Zealand
  1. Correspondence to : Dr Ralph A H Stewart, Department of Cardiology, Auckland City Hospital, Level 3, Building 32, Private Bag 92024, Victoria Street West, Auckland 1142, New Zealand; rstewart{at}adhb.govt.nz

https://doi.org/10.1136/eb-2013-101624

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Commentary on: Eikelboom JW, Connolly SJ, Brueckmann M, et al. Dabigatran versus warfarin in patients with mechanical heart valves. N Engl J Med 2013;369:1206.OpenUrlCrossRefPubMedWeb of Science

    Context

    Novel anticoagulants (including the direct thrombin inhibitor dabigatran etixilate) and oral factor Xa inhibitors have similar or superior efficacy and safety to warfarin for reducing thromboembolic stroke in patients with atrial fibrillation, and for prevention of deep venous thrombosis. Eikelboom and colleagues set out to examine whether these novel anticoagulants could be used as an alternative to warfarin in patients with mechanical heart valves.

    Methods

    RE-ALIGN was a randomised, open-label phase 2 trial with blinded adjudication of endpoints. Patients who had undergone aortic or mitral …

    View Full Text

    Footnotes

    • Competing interests None.